Peptide5 

Peptide5, a connexin 43 mimetic peptide, reduce animals swelling, astrogliosis, and neuronal cell death after spinal cord injury^[1]

Peptide5, significantly reduces the degree of spinal cord injury (SCI) in a rodent ex vivo model. Peptide5 produces the more significant reduction in swelling and is analyzed further. Treatment with peptide5 reduced both the level of Cx43 and the number of glial fibrillary acidic protein (GFAP)-positive astrocytes, and at the same time reduces the loss of NeuN- and SMI-32–positive neurons in a concentration- and time-dependent manner^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Peptide5 is could be used to treat traumatic spinal cord injured rats^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1395.58

C₆₀H₉₈N₁₆O₂₀S

916977-43-0

VDCFLSRPTEKT

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Simon J O'Carroll, et al. Connexin 43 mimetic peptides reduce swelling, astrogliosis, and neuronal cell death after spinal cord injury. Cell Commun Adhes. 2008 May;15(1):27-42.  [Content Brief]

  [2]. Yilin Mao, et al. Characterisation of Peptide5 systemic administration for treating traumatic spinal cord injured rats. Exp Brain Res. 2017 Oct;235(10):3033-3048.  [Content Brief]